Literature DB >> 31169665

Antimicrobials and Antiepileptics Are the Leading Causes of Idiosyncratic Drug-induced Liver Injury in American Children.

Frank DiPaola1, Jean P Molleston2, Jiezhun Gu3, Elizabeth T Cirulli3, Naga Chalasani2, Huiman Barnhart3, David E Kleiner4, Jay H Hoofnagle5, Robert J Fontana1.   

Abstract

OBJECTIVES: The aim of this study was to provide an overview of the presenting features, etiologies, and outcomes of children enrolled in the Drug-induced Liver Injury Network (DILIN) prospective and retrospective studies.
METHODS: Consecutive definite, highly likely, or probable cases in children enrolled into the ongoing DILIN prospective and retrospective studies between September 2004 and February 2017 were reviewed.
RESULTS: Fifty-seven cases were adjudicated as definite (14), highly likely (30), or probable (13) DILI. Median age was 14.3 years (1.7-17.9), 67% female, and 82% Caucasian. At DILI onset, 82% had hepatocellular injury with a median alanine aminotransferase of 411 U/L (33-4185), alkaline phosphatase 203 U/L (62-1177), and total bilirubin 3.3 mg/dL (0.2-33.9). The median duration of suspect medication use was 55 days (1-2789) and the most frequently implicated individual agents were minocycline (n = 11) and valproate (n = 6). Sixty-three percent were hospitalized and 3 (5%) underwent liver transplant within 1 month of DILI onset. Among 46 children followed for at least 6 months, 8 (17%) met criteria for chronic DILI with 6 of them having persistent liver injury at 24 months of follow-up. A genome-wide association study in 39 Caucasian children focusing on regions associated with pediatric cholestatic liver disease failed to demonstrate any single nucleotide polymorphism associated with DILI susceptibility or outcome.
CONCLUSIONS: Antimicrobials (51%) and antiepileptic drugs (21%) are the most frequently implicated agents in pediatric DILI patients. Although the majority of cases are self-limited, there is potential for serious morbidity including acute liver failure, chronic liver injury, and death.

Entities:  

Year:  2019        PMID: 31169665      PMCID: PMC6658343          DOI: 10.1097/MPG.0000000000002383

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  30 in total

1.  PLINK: a tool set for whole-genome association and population-based linkage analyses.

Authors:  Shaun Purcell; Benjamin Neale; Kathe Todd-Brown; Lori Thomas; Manuel A R Ferreira; David Bender; Julian Maller; Pamela Sklar; Paul I W de Bakker; Mark J Daly; Pak C Sham
Journal:  Am J Hum Genet       Date:  2007-07-25       Impact factor: 11.025

2.  Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles.

Authors:  M Isabel Lucena; Mariam Molokhia; Yufeng Shen; Thomas J Urban; Guruprasad P Aithal; Raúl J Andrade; Christopher P Day; Francisco Ruiz-Cabello; Peter T Donaldson; Camilla Stephens; Munir Pirmohamed; Manuel Romero-Gomez; Jose Maria Navarro; Robert J Fontana; Michael Miller; Max Groome; Emmanuelle Bondon-Guitton; Anita Conforti; Bruno H C Stricker; Alfonso Carvajal; Luisa Ibanez; Qun-Ying Yue; Michel Eichelbaum; Aris Floratos; Itsik Pe'er; Mark J Daly; David B Goldstein; John F Dillon; Matthew R Nelson; Paul B Watkins; Ann K Daly
Journal:  Gastroenterology       Date:  2011-04-12       Impact factor: 22.682

3.  ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history.

Authors:  Anne Davit-Spraul; Monique Fabre; Sophie Branchereau; Christiane Baussan; Emmanuel Gonzales; Bruno Stieger; Olivier Bernard; Emmanuel Jacquemin
Journal:  Hepatology       Date:  2010-05       Impact factor: 17.425

4.  Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method.

Authors:  Don C Rockey; Leonard B Seeff; James Rochon; James Freston; Naga Chalasani; Maurizio Bonacini; Robert J Fontana; Paul H Hayashi
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

5.  POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders.

Authors:  Russell P Saneto; Inn-Chi Lee; Mary Kay Koenig; Xinhua Bao; Shao-Wen Weng; Robert K Naviaux; Lee-Jun C Wong
Journal:  Seizure       Date:  2010-02-06       Impact factor: 3.184

6.  Incidence of drug-induced hepatic injuries: a French population-based study.

Authors:  Catherine Sgro; François Clinard; Kader Ouazir; Henry Chanay; Christian Allard; Christian Guilleminet; Claude Lenoir; Alain Lemoine; Patrick Hillon
Journal:  Hepatology       Date:  2002-08       Impact factor: 17.425

7.  Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct.

Authors:  Robert J Fontana; Paul B Watkins; Herbert L Bonkovsky; Naga Chalasani; Timothy Davern; Jose Serrano; James Rochon
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

8.  Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex.

Authors:  M Isabel Lucena; Raúl J Andrade; Neil Kaplowitz; Miren García-Cortes; M Carmen Fernández; Manuel Romero-Gomez; Miguel Bruguera; Hacibe Hallal; Mercedes Robles-Diaz; Jose F Rodriguez-González; Jose Maria Navarro; Javier Salmeron; Pedro Martinez-Odriozola; Ramón Pérez-Alvarez; Yolanda Borraz; Ramón Hidalgo
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

9.  Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity.

Authors:  Joanna D Stewart; Rita Horvath; Enrico Baruffini; Iliana Ferrero; Stefanie Bulst; Paul B Watkins; Robert J Fontana; Christopher P Day; Patrick F Chinnery
Journal:  Hepatology       Date:  2010-11       Impact factor: 17.425

10.  Effects of valproic acid on organic acid metabolism in children: a metabolic profiling study.

Authors:  K E Price; R E Pearce; U C Garg; B A Heese; L D Smith; J E Sullivan; M J Kennedy; J F Bale; R M Ward; T K H Chang; F S Abbott; J S Leeder
Journal:  Clin Pharmacol Ther       Date:  2011-05-04       Impact factor: 6.875

View more
  3 in total

1.  Causality Evaluation of Drug-Induced Liver Injury in Newborns and Children in the Intensive Care Unit Using the Updated Roussel Uclaf Causality Assessment Method.

Authors:  Ling Ye; Zeying Feng; Longjian Huang; Chengjun Guo; Xiong Wu; Li He; Wei Tan; Yi Wang; Xuehong Wu; Biwen Hu; Tong Li; Guoping Yang; Guo Chengxian; Qingnan He
Journal:  Front Pharmacol       Date:  2021-12-20       Impact factor: 5.810

2.  Therapeutic Management of Idiosyncratic Drug-Induced Liver Injury and Acetaminophen Hepatotoxicity in the Paediatric Population: A Systematic Review.

Authors:  Hao Niu; Edmond Atallah; Ismael Alvarez-Alvarez; Raul J Andrade; M Isabel Lucena; Inmaculada Medina-Caliz; Guruprasad P Aithal; Cigdem Arikan
Journal:  Drug Saf       Date:  2022-08-25       Impact factor: 5.228

3.  An electronic medical records-based approach to identify idiosyncratic drug-induced liver injury in children.

Authors:  Tracy L Sandritter; Jennifer L Goldman; Clayton J Habiger; James F Daniel; Jennifer Lowry; Ryan T Fischer
Journal:  Sci Rep       Date:  2019-12-02       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.